Abiomed: Best in Breed Healthcare Stock for 2016

A decent summary of why Abiomed might be poised to surge in the coming year. Via The Street:

As a small company, Abiomed clearly has growth on its side. Its three-year average revenue growth of 22.2% (vs. the industry’s decline) and net income growth of 323.7% (again, against the industry decline) is probably why investors are ready to place a premium valuation of 80.3 times for its forward earnings.

A gross margin in excess of 80% is not unheard of. What’s surprising is that Abiomed has grown margins even at this elevated rate. Gross margin for fiscal second quarter 2016 was 84.1% compared to 81.5% in the second quarter of fiscal 2015.

The company’s Impella brand of blood pumping devices continues to show strong growth. The company has increased its fiscal year 2016 guidance for total revenues to hover around $305 million-to-$315 million, up 32% to 37% from the previous year.

Read the entire article at http://www.thestreet.com/story/13405650/1/3-small-cap-best-i…

  • Matt

Hi Matt,
Congratulations on your CMF designations. You are going to be great at it. I can’t wait to see your write ups now that you have the keys to the kingdom. :slight_smile:


1 Like

Thanks Andy!

Yeh - second that Matt, congratulations. Nice of you to point out and recognize Andy.

1 Like